Group 1 - The top three companies with the highest short position ratios are ZTE Corporation (00763) at 15.37%, COSCO Shipping Holdings (01919) at 14.41%, and CATL (03750) at 13.38% [1][2] - The company with the largest increase in short position ratio is China Pacific Insurance (02601), which rose by 5.56% to 7.72% [2] - The companies with the largest decrease in short position ratio include Shandong Gold (01787), which decreased by 3.98% to 8.68%, and Kingsoft Cloud (03896), which decreased by 1.65% to 2.96% [1][3] Group 2 - The latest short position ratios for the top ten companies show that Zijin Mining (02899) has a ratio of 13.12%, Ping An Insurance (02318) at 12.68%, and MicroPort Medical (00853) at 11.92% [2] - The companies with the most significant increases in short position ratios also include Hengrui Medicine (01276) with an increase of 0.98% to 8.19% and Kanglong Chemical (03759) with an increase of 0.93% to 7.27% [2] - The companies with the most significant decreases in short position ratios also include Kangfang Biotech (09926) with a decrease of 1.02% to 3.89% and Shengye (06069) with a decrease of 0.99% to 1.83% [3]

Core Viewpoint - The company, Lai Kai Pharmaceutical-B (02105), has successfully completed the placement of 36 million shares at a price of HKD 16.30 per share, fulfilling all conditions of the placement agreement [1]. Group 1 - The placement was completed on September 17, 2025 [1]. - The shares were successfully placed by a sole placement agent to no fewer than six subscribers [1].

Group 1 - The company, 来凯医药-B (02105), announced that all conditions for the placement have been met and the placement was completed on September 17, 2025 [1] - A total of 36 million shares were successfully placed by the exclusive placement agent at a price of HKD 16.30 per share to no fewer than six subscribers [1]

表格類別： 股票 狀態： 新提交 公司名稱： 來凱醫藥有限公司 呈交日期： 2025年9月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02105 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考，並非收購、購買或認購本公司證券的邀請或要約。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的 任何其他司法權區內刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公 告所述證券並未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會 在美國提呈或出售，除非根據美國證券法作出登記或獲豁免或為毋須根據美國證 券 法 作 出 登 記 之 交 易 。 本 公 司 無 意 根 據 美 國 證 券 法 登 記 本 公 告 內 所 指 之 任 何 證 券，或在美國進行證券之公開發售。 Laekna, Inc. 來凱醫藥有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2105） 完成根據一般授權配售新股 獨家整體協調人及獨家配售代理 董 事 會 欣 然 宣 佈 ...

Core Viewpoint - 来凯医药-B plans to place 36 million shares, representing approximately 8.1% of the enlarged share capital post-placement, at a price of HKD 16.30 per share, which is about a 9.5% discount to the closing price of HKD 18.01 on September 9 [1] Fundraising Details - The total expected fundraising amount is HKD 586.8 million, with net proceeds estimated at HKD 577.5 million [1] - Approximately 90% of the raised funds will be allocated to the research and development of clinical and pre-clinical pipeline projects, while the remaining 10% will be used for general and corporate purposes [1]

Core Viewpoint - The company, 来凯医药-B (02105.HK), has announced a placement agreement to issue 36 million shares at a price of HKD 16.30 per share, which represents approximately 8.8% of the current issued share capital and about 8.1% of the enlarged issued share capital after the placement [1] Summary by Relevant Sections - **Placement Details** - The company will issue a total of 36 million shares through an exclusive placement agent [1] - The placement price is set at HKD 16.30 per share [1] - **Financial Implications** - The estimated gross proceeds from the placement will be approximately HKD 586.8 million, with net proceeds expected to be around HKD 577.5 million [1] - **Use of Proceeds** - Approximately 90% of the net proceeds will be allocated for research and development of clinical and pre-clinical pipeline projects [1] - The remaining 10% will be used for general and corporate purposes [1]

Core Viewpoint - The company plans to issue a total of 36 million placement shares, representing approximately 8.1% of the enlarged issued share capital post-completion, at a price of HKD 16.30 per share, which is a discount of about 9.5% compared to the closing price of HKD 18.01 on September 9 [1] Summary by Relevant Categories Fundraising Details - The total amount raised from the placement, assuming all shares are fully subscribed, will be HKD 586.8 million, with the estimated net proceeds from the placement being HKD 577.5 million [1] Use of Proceeds - Approximately 90% of the net proceeds will be allocated to research and development of clinical and pre-clinical pipeline projects, while about 10% will be used for general and corporate purposes [1]

Group 1 - The company, 来凯医药-B (02105), announced a proposed placement of 36 million shares, representing approximately 8.1% of the enlarged issued share capital post-completion [1] - The placement price is set at HKD 16.30 per share, which reflects a discount of about 9.5% compared to the closing price of HKD 18.01 on September 9 [1] - If all 36 million shares are fully subscribed, the total proceeds from the placement will amount to HKD 586.8 million, with the estimated net proceeds being HKD 577.5 million [1] Group 2 - Approximately 90% of the net proceeds from the placement will be allocated to research and development of clinical and preclinical pipeline projects [1] - The remaining 10% of the net proceeds will be used for general and corporate purposes [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考，並非收購、購買或認購本公司證券的邀請或要約。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的 任何其他司法權區內刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公 告所述證券並未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會 在美國提呈或出售，除非根據美國證券法作出登記或獲豁免或為毋須根據美國證 券 法 作 出 登 記 之 交 易 。 本 公 司 無 意 根 據 美 國 證 券 法 登 記 本 公 告 內 所 指 之 任 何 證 券，或在美國進行證券之公開發售。 Laekna, Inc. 來凱醫藥有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2105） 根據一般授權配售新股 獨家整體協調人及獨家配售代理 董 事 會 欣 然 宣 佈 ， ...